Canaccord raised the firm’s price target on Staar Surgical to $46 from $32 and keeps a Hold rating on the shares. The firm updated its model to reflect the company’s revenue preannouncement and said given there was no commentary on below-the-line performance in the press release, they are being conservative until the company reports full Q1 earnings on May 8th.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Staar Surgical upgraded to Outperform after Q1 beat at William Blair
- Staar Surgical upgraded to Outperform from Market Perform at William Blair
- Staar Surgical reports preliminary Q1 revenue in excess of $77M, consensus $72M
- Staar Surgical Highlights Milestone and Investor Engagement
- Staar Surgical initiated with an Outperform at CICC
